CY1110848T1 - Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση - Google Patents

Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση

Info

Publication number
CY1110848T1
CY1110848T1 CY20101100934T CY101100934T CY1110848T1 CY 1110848 T1 CY1110848 T1 CY 1110848T1 CY 20101100934 T CY20101100934 T CY 20101100934T CY 101100934 T CY101100934 T CY 101100934T CY 1110848 T1 CY1110848 T1 CY 1110848T1
Authority
CY
Cyprus
Prior art keywords
human
pharmaceutical
nogo
antique
binding molecule
Prior art date
Application number
CY20101100934T
Other languages
Greek (el)
English (en)
Inventor
Carmen Barske
Anis Khurso Mir
Thomas Oertle
Lisa Schnell
Martin E Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110848T1 publication Critical patent/CY1110848T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20101100934T 2002-12-10 2010-10-19 Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση CY1110848T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
EP03782350A EP1572745B1 (en) 2002-12-10 2003-12-09 Antibody anti human nogo a and its pharmaceutical use

Publications (1)

Publication Number Publication Date
CY1110848T1 true CY1110848T1 (el) 2015-06-10

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100934T CY1110848T1 (el) 2002-12-10 2010-10-19 Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση

Country Status (24)

Country Link
US (2) US7785593B2 (https=)
EP (1) EP1572745B1 (https=)
JP (1) JP4504200B2 (https=)
KR (1) KR101215801B1 (https=)
CN (1) CN100384877C (https=)
AT (1) ATE475671T1 (https=)
AU (1) AU2003289998B2 (https=)
BR (1) BR0317161A (https=)
CA (1) CA2509068C (https=)
CY (1) CY1110848T1 (https=)
DE (1) DE60333585D1 (https=)
DK (1) DK1572745T3 (https=)
EC (1) ECSP055849A (https=)
ES (1) ES2349293T3 (https=)
GB (1) GB0228832D0 (https=)
IL (1) IL169018A (https=)
MX (1) MXPA05006265A (https=)
NO (1) NO20053304L (https=)
PL (1) PL210720B1 (https=)
PT (1) PT1572745E (https=)
RU (1) RU2350623C2 (https=)
SI (1) SI1572745T1 (https=)
WO (1) WO2004052932A2 (https=)
ZA (1) ZA200504522B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
KR20080030960A (ko) * 2005-07-05 2008-04-07 글락소 그룹 리미티드 Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
HRP20130699T1 (hr) 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN105491883B (zh) * 2013-06-13 2018-11-02 生物马特里卡公司 细胞稳定化
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021079002A2 (en) * 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
IL150566A0 (en) 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
EP1461300B1 (en) * 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
ES2349293T3 (es) 2010-12-29
JP4504200B2 (ja) 2010-07-14
BR0317161A (pt) 2005-11-01
GB0228832D0 (en) 2003-01-15
AU2003289998B2 (en) 2008-02-14
PL377506A1 (pl) 2006-02-06
US8535666B2 (en) 2013-09-17
PT1572745E (pt) 2010-10-21
JP2006523087A (ja) 2006-10-12
CA2509068C (en) 2012-02-07
PL210720B1 (pl) 2012-02-29
KR101215801B1 (ko) 2012-12-26
US7785593B2 (en) 2010-08-31
RU2350623C2 (ru) 2009-03-27
CN1747971A (zh) 2006-03-15
WO2004052932A2 (en) 2004-06-24
DE60333585D1 (de) 2010-09-09
CN100384877C (zh) 2008-04-30
IL169018A (en) 2012-07-31
EP1572745B1 (en) 2010-07-28
NO20053304L (no) 2005-09-07
RU2005121669A (ru) 2007-01-20
ECSP055849A (es) 2005-09-20
EP1572745A2 (en) 2005-09-14
MXPA05006265A (es) 2005-12-05
KR20050095768A (ko) 2005-09-30
SI1572745T1 (sl) 2010-12-31
DK1572745T3 (da) 2010-10-25
NO20053304D0 (no) 2005-07-06
CA2509068A1 (en) 2004-06-24
ZA200504522B (en) 2006-03-29
WO2004052932A3 (en) 2004-10-21
US20060183678A1 (en) 2006-08-17
HK1084676A1 (en) 2006-08-04
AU2003289998A1 (en) 2004-06-30
ATE475671T1 (de) 2010-08-15
US20110059110A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
EA200700136A1 (ru) Анти-cd154-антитела
WO2007039818A8 (en) Antigen binding molecules having modified fc regions and altered binding to fc receptors
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
CY1115920T1 (el) Αντι-gm-csf αντισωματα και χρησεις αυτων
EP3660510A3 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
WO2006087637A3 (en) Anti her2/neu antibody
TW200635946A (en) Binding proteins specific for human matriptase
AR036154A1 (es) Anticuerpos especificos de cd44v6.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
BRPI0414174B8 (pt) anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
PE20250753A1 (es) Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
Cozma Determination of Primary Structure and Affinity Characterization of Naturally Occurring β-Amyloid Autoantibodies
BRPI0309730B8 (pt) molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica